SNP
|
RORi(95%CI)
|
P
|
SNP carriers
|
SNP noncarriers
|
Anti-CCP+patients
|
---|
OR
PTPN22
(95% CI)
|
OR
PTPN22
(95%CI)
|
RORi(95% CI)
|
P
|
---|
rs7726839
|
1.08 (0.75 to 1.55)
|
0.70
|
1.56 (1.18 to 2.07)
|
1.45 (1.15 to 1.83)
|
1.23 (0.8 to 1.9)
|
0.34
|
rs12573019
|
0.74 (0.49 to 1.12)
|
0.15
|
1.19 (0.83 to 1.71)
|
1.61 (1.31 to 1.98)
|
0.63 (0.38 to 1.04)
|
0.07
|
rs1168587
|
0.84 (0.58 to 1.22)
|
0.35
|
1.40 (1.11 to 1.76)
|
1.68 (1.24 to 2.24)
|
0.92 (0.59 to 1.43)
|
0.71
|
rs1895535
|
0.66 (0.36 to 1.20)
|
0.17
|
1.02 (0.58 to 1.80)
|
1.56 (1.25 to 1.92)
|
0.84 (0.39 to 1.8)
|
0.66
|
rs7200573
|
1.14 (0.8 to 1.63)
|
0.47
|
1.60 (1.24 to 2.07)
|
1.40 (1.10 to 1.80)
|
1.26 (0.82 to 1.93)
|
0.28
|
rs11865624
|
1.15 (0.68 to 1.94)
|
0.59
|
1.69 (1.04 to 2.75)
|
1.47 (1.21 to 1.78)
|
1.35 (0.72 to 2.53)
|
0.36
|
- aData show lack of replication between the six single-nucleotide polymorphisms (SNPs) and the PTPN22 rheumatoid arthritis (RA) locus in the whole set of RA patients and controls (left) and in the comparison of anti–cyclic citrullinated peptide–positive (anti-CCP+) patients with controls (last two columns on the right). PTPN22, Protein tyrosine phosphatase nonreceptor type 22; RORi, Ratio of odds ratios of the interaction.